Physician profile
Raj S Rathee
NPI 1902885593
$4,352.39
in general payments reported to CMS, 2019-2025
27 companies · $603 in 2025
The $603 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $310 · 2021: $313 · 2022: $848 · 2023: $657 · 2024: $611 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.75 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,393.06 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $643.29 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $552.43 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $374.79 | 2021-2022 | |
| Minerva Surgical, INC | $207.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.11 | 2019-2025 | |
| Hologic Sales and Service, LLC | $143.69 | 2022-2025 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Organon LLC | $139.61 | 2022-2025 | Nexplanon |
| Coopersurgical, INC. | $81.61 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $81.23 | 2022-2024 | |
| Medtronic, INC. | $78.68 | 2022-2024 | Interstim, Micra |
| Lupin INC. | $72.30 | 2019 | |
| Daiichi Sankyo INC. | $59.48 | 2019 | |
| Davol INC. | $45.83 | 2024 | Arista Ah Flexitip |
| Mayne Pharma Commercial LLC | $44.57 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $42.33 | 2022-2023 | Ethicon, Stratafix, Dermabond |
| Covidien LP | $24.93 | 2019 | |
| Amag Pharmaceuticals, INC. | $23.94 | 2019 | |
| Aspira Women'S Health INC | $22.38 | 2024 | Ova1 |
| Duchesnay USA Incorporated | $22.37 | 2019 | |
| Allergan, INC. | $18.52 | 2019 | |
| Avion Pharmaceuticals | $18.00 | 2019 | |
| Therapeuticsmd, INC. | $17.71 | 2022 | |
| Merck Sharp & Dohme LLC | $16.29 | 2023 | Vaxneuvance |
| Shield Therapeutics INC | $13.80 | 2024 | |
| Alexion Pharmaceuticals, INC. | $12.00 | 2019 | |
| Exeltis, USA INC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Rathee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.